← Leaderboards
Edward J Filardo
Rhode Island Hospital
$3,211,307
Attributed
$3,211,307
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2007–24$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,211,307 · 2
By mechanism
R44$2,042,215 · 1
R01$1,169,092 · 1
Top collaborators
No co-investigators on record.
Most similar at Rhode Island Hospital
Same institution · by research overlap
- Qian Chen$25,602,425
- Yupeng Chen$3,774,169
- Olin D. Liang$4,082,589
- Yupeng Chen$2,049,750
- Wentian Yang$4,477,149
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellMembraneSurfaceProgramsGrowthBiologicalNeoplasm MetastasisSerumDesignTumorDiagnosisEnzymesBiochemicalBiopsyBinding (Molecular Function)Epidermal Growth FactorCoupledBehaviorBreast Cancer CellCell SurvivalAdenylate CyclaseCellular BiologyCyclic AmpCell Membrane
Grant awards (6)
Development of CA-IL-12 for Triple Negative Breast Cancer$893,673
R44 · FY2024 · CA · contact PI
Development of CA-IL-12 for Triple Negative Breast Cancer$1,148,542
R44 · FY2023 · CA · contact PI
Study of GPR30: a novel estrogen receptor linked to breast cancer.$292,011
R01 · FY2010 · CA · contact PI
Study of GPR30: a novel estrogen receptor linked to breast cancer.$291,700
R01 · FY2009 · CA · contact PI
Study of GPR30: a novel estrogen receptor linked to breast cancer.$297,606
R01 · FY2008 · CA · contact PI
Study of GPR30: a novel estrogen receptor linked to breast cancer.$287,775
R01 · FY2007 · CA · contact PI